Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design-Reference-Cited by-同舟云学术

Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design

Published:2020-12 Issue: Volume:20 Page:100678
ISSN:2451-8654
Container-title:Contemporary Clinical Trials Communications
language:en
Short-container-title:Contemporary Clinical Trials Communications

Author:

Sampayo-Cordero Miguel,Miguel-Huguet Bernat,Pérez-García José,Páez David,Guerrero-Zotano Ángel L.,Garde-Noguera Javier,Aguirre Elena,Holgado Esther,López-Miranda Elena,Huang Xin,Malfettone Andrea,Llombart-Cussac Antonio,Cortés Javier

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference52 articles.

1. 18F-fluoromisonidazole PET and activity of neoadjuvant Nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial;Quintela-Fandino;Clin. Canc. Res.,2017

2. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial;Llombart-Cussac;Lancet Oncol.,2017

3. More randomization in phase II trials: necessary but not sufficient;Rubinstein;J. Natl. Cancer Inst.,2011

4. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases;Sampayo-Cordero;Orphanet J. Rare Dis.,2019

5. A proof of concept phase II non-inferiority criterion;Neuenschwander;Stat. Med.,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer;Frontiers in Oncology;2023-07-11

2. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met;European Journal of Cancer;2021-12

3. The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis”;Frontiers in Molecular Biosciences;2021-06-22